AMENDMENTS TO THE CLAIMS:

1. (Currently amended) A method of treating a wound in an animal or human comprising administering to said animal or human a pharmaceutical composition comprising a lipopeptide or lipoprotein with the following general structure:



wherein

R^1 and R^2 stand for C_{7-25}-alkyl, C_{7-25}-alkenyl or ~~C_{7-25}-alkinyl~~ C_{7-25}-alkynyl,

X is S, O, or CH_2,

Z^1 and Z^2 stand for H or methyl,

W stands for CO or $S(O)_n$ (where n = 1 or 2) and

Y ~~stands for a physiologically compatible amino acid sequence consisting of 1 to 25 amino acid residues~~ comprises the following amino acid sequence:

GNNDESNISFKEK (SEQ ID NO:3);

or a fragment or variant thereof, wherein the lipopeptide or lipoprotein with said fragment or variant has macrophage stimulating activity,

and the asymmetric carbon atom marked with * denotes an asymmetric carbon atom and has the absolute configuration R when X = S (sulfur).

2. (Canceled)

3. (Canceled)

4. (Currently amended) The method of claim 1 wherein the C_{7-25}-alkyl, C_{7-25}-alkenyl, or ~~C_{7-25}-alkinyl~~ C_{7-25}-alkynyl is a C_{15}-alkyl, C_{15}-alkenyl, or ~~C_{15}-alkinyl~~ C_{15}-alkynyl, respectively.

5. (Withdrawn) The method of claim 1 wherein the double bond(s) in the C_{7-25}-alkenyl group has(have) the cis-configuration.

6. (Currently amended) A method of treating a wound in an animal or human comprising administering to an animal or human a physiologically compatible lipopeptide or lipoprotein which carries at the N-terminal a dihydroxypropyl cysteine group with two fatty acids bonded via ester bonds, wherein the lipopeptide or lipoprotein comprises the following amino acid sequence:

GNNDESNISFKEK (SEQ ID NO:3);

or a fragment or variant thereof, wherein the lipopeptide or lipoprotein with said fragment or variant has macrophage stimulating activity.

7. (Previously presented) The method of claim 1 wherein said lipopeptide or lipoprotein is obtained from a mycoplasma clone.

8. (Previously presented) The method of Claim 7, wherein said lipopeptide or lipoprotein is obtained from a *Mycoplasma fermantans* clone.

9. (Currently amended) The method of claim 1 wherein said ~~the~~ lipopeptide or lipoprotein is water-soluble or amphoteric.

10. (Currently amended) The method of claim 1 wherein said lipopeptide or lipoprotein ~~selected from the group consists of~~ comprises:

~~(i) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-GQTNT (SEQ ID NO:5)~~

~~(ii) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-SKKKK (SEQ ID NO:6)~~

~~(iii)~~ (i) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-GNNDESNISFKEK (SEQ ID NO:7)

~~(iv) S-[2,3-bispalmitoyloxy-(2S)-propyl]cysteinyl-GNNDESNISFKEK (SEQ ID NO:8)~~

~~(v) S-[2,3-bispalmitoyloxypropyl]cysteinyl-GQTDNNSSQSQQPGSGTTNT (SEQ ID NO:9) and~~

~~(vi)~~(ii) S-[2,3-bispalmitoyloxy-(2R)-propyl]cysteinyl-GNNDESNISFKEK (SEQ ID NO:10).

11. (Previously presented) The method of claim 1 wherein said lipopeptide or lipoprotein is in the form of a solution for epicutaneous application, an injection solution, a salve, a lotion, an aqueous suspension, a plaster impregnated or coated with said lipopeptide or lipoprotein, encapsulated in liposomes, or coupled to biodegradable carrier polymers.

12. (Previously presented) The method of claim 1 wherein said wounds are wounds after injury or surgical intervention, chronically infected wounds, burn wounds, chronic ulcers or Ulcus venosum or wounds of patients who are corpulent or diabetic or are subjected to radiation or chemotherapy.